Aslan to reduce headcount, operating costs to support upcoming milestones

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Tuesday it will reduce headcount by 30% and slash operating costs by 50%.

The restructuring will help support Aslan well into 2020 as it focuses operations

Read the full 326 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE